Advertisement
CI vs CVS
Which Stock Would AI Choose? The Cigna Group (CI) vs. CVS Health (CVS) Stock Comparison
Key Takeaways
- Both CI and CVS are diversified healthcare companies, but CI leans toward employer-sponsored insurance and pharmacy services, while CVS pairs insurance (Aetna) with the nation's largest retail pharmacy chain.
- CVS has shown stronger recent momentum, rallying more than 20% in 2026 on a series of beat-and-raise quarters, while CI's shares have advanced more modestly amid uncertainty around its pharmacy benefit manager (PBM) transition.
- Both companies are repricing and reshaping their PBM models under rising regulatory scrutiny, a shared risk that has weighed on sentiment for the sector.
- CI's medical cost trends and specialty pharmacy growth have supported margins, whereas CVS's improving medical benefit ratio (MBR) has driven its turnaround narrative.
- Relative positioning favors CVS on near-term catalysts, while CI screens as a higher-margin, more focused play on employer health services.
Introduction
Investors weighing healthcare exposure frequently encounter two of the largest and most recognizable names in the industry: The Cigna Group (CI) and CVS Health (CVS). Although both operate across insurance, pharmacy benefit management, and care delivery, their business mixes, growth drivers, and recent price behavior differ meaningfully. This stock comparison is relevant for traders and investors seeking to understand which of these two healthcare giants offers the more compelling risk-reward profile in the current market. By examining relative performance, market positioning, and observable catalysts, readers can better assess how each name fits a diversified portfolio or an active trading strategy.
CI Overview and Recent Performance
The Cigna Group is a global health services company anchored by Evernorth Health Services — which houses its pharmacy benefit manager (PBM) and specialty pharmacy operations — and Cigna Healthcare, its employer-focused insurance segment. In recent quarters the company has concentrated its portfolio on commercial health and high-growth specialty care, following the 2025 divestiture of its Medicare businesses and a planned exit from the individual exchange market.
Recent market activity has reflected a blend of solid fundamentals and strategic uncertainty. CI posted first-quarter 2026 revenue of roughly $68.5 billion and adjusted earnings per share (EPS) of $7.79, above consensus, and subsequently raised its full-year outlook. Specialty pharmacy volumes and biosimilar adoption have supported margins, while management has emphasized a new rebate-free pharmacy model and AI-driven efficiency initiatives. At the same time, the shares have traded with a discount to analyst price targets, as investors weigh the multi-year execution risk around its PBM transition and broader regulatory pressure. Sentiment has remained constructive but measured, with a prevailing "Strong Buy" analyst consensus and an average target implying meaningful upside from recent levels near $300.
CVS Overview and Recent Performance
CVS Health operates a vertically integrated model spanning three segments: Health Care Benefits (Aetna), Health Services (the Caremark PBM), and Pharmacy & Consumer Wellness, which includes the country's largest retail pharmacy network. This diversification gives CVS direct exposure to government insurance programs, employer plans, pharmacy services, and front-store retail — a mix that has historically produced both scale and volatility.
Recent performance has favored CVS. The company delivered a strong first-quarter 2026 report, with revenue of roughly $100.4 billion and adjusted EPS of $2.57 that beat estimates, then raised its full-year guidance. Its medical benefit ratio (MBR) — the share of premiums spent on medical claims — improved to 84.6% from 87.3% a year earlier, a key signal that its insurance turnaround is gaining traction. Management has executed a broad cost-reduction program, closed underperforming stores, and reshaped leadership. These factors helped drive the stock to a notable rally, with shares up more than 20% in 2026 and reaching 52-week highs. However, the gains have not come without friction: management has flagged expected Caremark membership declines and a 340B program headwind extending into 2027, which tempered enthusiasm after strong earnings prints.
Trending AI Robots
Tickeron's Trending AI Robots page curates a focused selection of the platform's best-performing AI trading bots for current market conditions. Tickeron maintains hundreds of AI trading bots that collectively trade thousands of different tickers, yet only a subset earns a place in this trending section. The page highlights roughly 21 featured bots selected from a broader universe of more than 300, showcasing metrics such as realized return, win rate, profit factor, and profit-to-drawdown ratio. Each bot operates with its own trading style, strategy, timeframe, and set of tickers, so performance and statistics vary considerably from one bot to the next. For traders and investors comparing names like CI and CVS, reviewing the Trending AI Robots section can provide an additional, data-driven perspective on which stocks AI currently favors.
Head-to-Head Comparison
The clearest contrast between CI and CVS is business-model breadth. CI has narrowed its focus toward employer-sponsored health benefits and specialty pharmacy, producing higher structural margins but concentrating its exposure on commercial PBM economics. CVS, by contrast, spans retail, government insurance, and PBM services — a wider footprint that offers diversification but also carries higher balance-sheet leverage and more operational complexity.
On momentum, CVS currently holds the edge. Its turnaround has translated into consecutive guidance raises and a sharply improved medical benefit ratio, fueling a stronger 2026 share-price advance. CI's relative performance has been steadier but less dynamic, held back by questions around its PBM repricing strategy and client retention. Both face shared regulatory headwinds tied to PBM transparency, yet CVS's retail and insurance businesses provide offsetting revenue streams that CI's more focused model does not.
From a risk standpoint, CI's concentrated commercial exposure makes it sensitive to employer client losses, while CVS's debt load and still-elevated medical costs remain watch items. Investors seeking a higher-margin, services-led franchise may find CI's profile attractive, whereas those looking for a diversified turnaround with near-term catalysts may gravitate toward CVS.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely tilt toward CVS at present. The stock's trend consistency, improving medical benefit ratio, and series of raised guidance signals reflect a more favorable near-term catalyst path than CI, whose story is burdened by multi-year PBM transition uncertainty. That said, the assessment is probabilistic rather than definitive: CI's stronger margins and lower leverage could warrant a more constructive view if its pharmacy model transition proceeds smoothly. Both names carry sector-wide regulatory risk, so AI-driven positioning would likely depend on which catalysts continue to develop most favorably in the weeks ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CI is a Buy and CVS is a Hold.
CI in upward trend: price rose above 50-day moving average on October 07, 2026
CI moved above its 50-day moving average on October 07, 2026 date and that indicates a change from a downward trend to an upward trend. In 38 of 52 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on CI as a result. In 61 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for CI just turned positive on October 07, 2026. Looking at past instances where CI's MACD turned positive, the stock continued to rise in 32 of 50 cases over the following month. The odds of a continued upward trend are 64%.
The 10-day moving average for CI crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
The 50-day moving average for CI moved above the 200-day moving average on October 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +4.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where CI advanced for three days, in 222 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
CI broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CI entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.887) is normal, around the industry mean (3.582). P/E Ratio (12.520) is within average values for comparable stocks, (130.390). Projected Growth (PEG Ratio) (0.739) is also within normal values, averaging (0.786). CI has a moderately high Dividend Yield (0.021) as compared to the industry average of (0.009). P/S Ratio (0.264) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 26 (best 1 - 100 worst), indicating outstanding price growth. CI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 41 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
CVS in upward trend: price rose above 50-day moving average on October 15, 2026
CVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 36 of 51 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on CVS as a result. In 59 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for CVS just turned positive on October 06, 2026. Looking at past instances where CVS's MACD turned positive, the stock continued to rise in 32 of 50 cases over the following month. The odds of a continued upward trend are 64%.
Following a +2.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVS advanced for three days, in 228 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
The 10-day RSI Indicator for CVS moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 22 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 61%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
CVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CVS entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CVS's P/B Ratio (1.500) is slightly lower than the industry average of (3.582). P/E Ratio (24.463) is within average values for comparable stocks, (130.390). CVS's Projected Growth (PEG Ratio) (0.206) is slightly lower than the industry average of (0.786). CVS has a moderately high Dividend Yield (0.028) as compared to the industry average of (0.009). P/S Ratio (0.283) is also within normal values, averaging (0.569).
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating fairly steady price growth. CVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
CI | CVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 36 | 25 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 21 Undervalued | |
PROFIT vs RISK RATING 1..100 | 41 | 71 | |
SMR RATING 1..100 | 55 | 81 | |
PRICE GROWTH RATING 1..100 | 26 | 45 | |
P/E GROWTH RATING 1..100 | 73 | 33 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CVS's Valuation (21) in the Drugstore Chains industry is in the same range as CI (24) in the Managed Health Care industry. This means that CVS’s stock grew similarly to CI’s over the last 12 months.
CI's Profit vs Risk Rating (41) in the Managed Health Care industry is in the same range as CVS (71) in the Drugstore Chains industry. This means that CI’s stock grew similarly to CVS’s over the last 12 months.
CI's SMR Rating (55) in the Managed Health Care industry is in the same range as CVS (81) in the Drugstore Chains industry. This means that CI’s stock grew similarly to CVS’s over the last 12 months.
CI's Price Growth Rating (26) in the Managed Health Care industry is in the same range as CVS (45) in the Drugstore Chains industry. This means that CI’s stock grew similarly to CVS’s over the last 12 months.
CVS's P/E Growth Rating (33) in the Drugstore Chains industry is somewhat better than the same rating for CI (73) in the Managed Health Care industry. This means that CVS’s stock grew somewhat faster than CI’s over the last 12 months.
| CI | CVS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 64% | 1 day ago 61% |
| Stochastic ODDS (%) | 1 day ago 57% | 1 day ago 62% |
| Momentum ODDS (%) | 1 day ago 64% | 1 day ago 67% |
| MACD ODDS (%) | 1 day ago 64% | 1 day ago 64% |
| TrendWeek ODDS (%) | 1 day ago 60% | 1 day ago 63% |
| TrendMonth ODDS (%) | 1 day ago 62% | 1 day ago 60% |
| Advances ODDS (%) | 7 days ago 63% | 3 days ago 67% |
| Declines ODDS (%) | 22 days ago 55% | 14 days ago 61% |
| BollingerBands ODDS (%) | 1 day ago 62% | 1 day ago 68% |
| Aroon ODDS (%) | 1 day ago 51% | 1 day ago 63% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CI’s FA Score shows that 2 FA rating(s) are green while CVS’s FA Score has 2 green FA rating(s).
- CI’s FA Score: 2 green, 3 red.
- CVS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CI’s TA Score shows that 6 TA indicator(s) are bullish while CVS’s TA Score has 4 bullish TA indicator(s).
- CI’s TA Score: 6 bullish, 5 bearish.
- CVS’s TA Score: 4 bullish, 5 bearish.
Price Growth
CI (@Managed Health Care) experienced а +5.71% price change this week, while CVS (@Managed Health Care) price change was +3.39% for the same time period.
The average weekly price growth across all stocks in the @Managed Health Care industry was +2.49%. For the same industry, the average monthly price growth was +10.42%, and the average quarterly price growth was +42.97%.
Reported Earning Dates
CI is expected to report earnings on Nov 05, 2026.
CVS is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Managed Health Care (+2.49% weekly)Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.
Advertisement
CVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, CVS has been loosely correlated with UNH. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if CVS jumps, then UNH could also see price increases.